Revealing the changes in signaling pathways caused by tofacitinib in patients with rheumatoid arthritis through RNA sequencing and the correlation with clinical parameters
Authors:
- 16 March 2024
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (5) , 1479-1489
Abstract
Objectives The current study is to accelerate the understanding of how tofacitinib works in patients with rheumatoid arthritis (RA) due to the lack of relevant information. Method We selected ten patients with active RA and obtained the expression profile for their peripheral blood mononuclear cells before and after the tofacitinib treatment by RNA sequencing. The gene set enrichment analysis was conducted, and the significantly enriched gene sets were identified. The hub gene highly correlated with clinical parameters in the gene set was selected. We constructed the weighted gene co-expression network, linked modules with clinical indicators, and screened hub genes. The expression of representative hub genes was validated by real-time quantitative PCR (qPCR). Results Gene set interferon (IFN) α and IFN β signaling was the most significantly down-regulated after tofacitinib treatment. In this gene set, genes Oas2 and Oasl showed a significant positive correlation with morning stiffness. In co-expression network, gene Vgll3 from the violet module with the highest correlation coefficient, was positively correlated with morning stiffness. Among them, Oasl and Vgll3 have shown significant down-regulation in qPCR validation. Conclusions Our results highlighted the role of type I IFN, mainly including IFN α and IFN β, in the pathogenesis of RA and action for tofacitinib, and provided a new entry point for further elucidating the mechanism of morning stiffness. Key Points • Gene set IFN α and IFN β signaling was the most significantly down-regulated after tofacitinib treatment in RA patients. • Gene Oasl and Vgll3 were correlated with morning stiffness and significantly down-regulated due to the action of tofacitinib. • Type I IFN system was highlighted in the action of tofacitinib.Keywords
Funding Information
- National Natural Science Foundation of China (No.82002844)
- Natural Science Foundation of Shandong Province of China (No. ZR2020QH120, No. ZR2021QH007)
This publication has 23 references indexed in Scilit:
- OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosisNature Cell Biology, 2023
- Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritisExpert Review of Clinical Immunology, 2022
- Rheumatoid Arthritis Morning Stiffness Is Associated With Synovial Fibrin and NeutrophilsArthritis & Rheumatology, 2019
- STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasetsNucleic Acids Research, 2018
- Oligoadenylate synthase-like (OASL) proteins: dual functions and associations with diseasesExperimental & Molecular Medicine, 2015
- Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome‐Wide DNA MicroarrayArthritis & Rheumatology, 2014
- Application of ggplot2 to Pharmacometric GraphicsCPT: Pharmacometrics & Systems Pharmacology, 2013
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Molecular signatures database (MSigDB) 3.0Bioinformatics, 2011
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003